FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer

NovoCure Ltd

FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.
Median overall survival improved to 16.2 months vs 14.2 months (HR 0.82, p=0.039).
Time to pain progression extended by 6.1 months (15.2 vs 9.1 months).
First new treatment approved for locally advanced pancreatic cancer in nearly 30 years.
Optune Pax well-tolerated; most adverse events were mild-to-moderate skin reactions under arrays.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.